26 results about "Brain edema" patented technology

The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo decompressive therapy.

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

The application provides a craniocerebral injury simulation man teaching model, which comprises a simulation man body provided with a head, a body and limbs; the head is internally provided with a craniocerebral simulation unit for simulating brain edema, brain hematoma, brain fracture, brain hernia and cerebrospinal fluid leakage; the body is internally provided with a urinary system simulation unit, a blood circulation system simulation unit and a respiratory system simulation unit; the controller is prearranged with control programs of reactions of the urinary system simulation unit, the blood circulation system simulation unit and the respiratory system simulation unit corresponding to different brain injuries; an operator selects different brain injuries and carries out nursing on the brain injuries and the complications of the urinary system simulation unit, the blood circulation system simulation unit and the respiratory system simulation unit. The application can not only nurse the brain injuries through the craniocerebral simulation unit, but also nurse the complications of the brain injuries through the urinary system simulation unit, the blood circulation system simulation unit and the respiratory system simulation unit, so that the application is more consistent with the actual situation and is beneficial to teaching.

How to treat injuries or conditions associated with CNS edema [Solution] This technology relates to reducing or treating neurological swelling and related conditions with SUR1-TRPM4 channel inhibitors. In some embodiments, the method includes reducing late neurological exacerbations or preventing death, reducing midline deviation of the brain, reducing the degree of functional impairment in subjects, neutralizing blood glucose levels in subjects receiving SUR1-TRPM4 channel inhibitors, preventing cerebral swelling, treating injuries or conditions associated with CNS edema while monitoring liver enzyme activity, or treating injuries or conditions associated with CNS edema while monitoring cardiac activity.

The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo decompressive therapy.

The invention provides a method for quantifying a water content ratio, which comprises the following steps of: scanning a brain by using first energy and second energy through dual-energy CT (Computed Tomography) equipment to generate plain scanning data of each voxel; setting the three substances of the dual-energy tomography three-substance separation mathematical model as water, grey matter and white matter; processing the plain scanning data of each voxel by using the dual-energy tomography three-substance separation mathematical model to obtain enhanced data of each voxel; and calculating the water content percentage of each voxel according to the enhancement data of each voxel. The method for quantifying the water content can quantify the water content of the encephaledema tissue of the acute stroke patient, and further quantify the edema proportion of the encephaledema tissue. The invention further provides a water content ratio quantifying device, a tomography system and a storage medium which relate to the method.

The invention belongs to the technical field of animal model construction, and discloses a construction method and application of a mouse encephaledema model. The construction method of the encephaledema model is simple and convenient to operate, simple and easy to repeat, stable in injury, high in success rate and low in death rate, and the encephaledema model can be obtained only by applying 0.4-0.6 W ultrasonic stimulation to the brain of an animal. Parameters can be adjusted according to actual needs, so that the damage degree is changed, the research purpose is met, and high controllability is achieved. The construction method provides a new research model for in-vivo research of the occurrence and development process and mechanism of encephaledema.

The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors. In some embodiments, the SUR1-TRPM4 channel inhibitor is used in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a baseline NIHSS of ≤ 20. In certain embodiments, patients have a lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo treatment with a thrombolytic agent and / or decompressive therapy.

To provide the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors in combination with mechanical thrombectomy.SOLUTION: In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, the patients have a lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo decompressive therapy.SELECTED DRAWING: None

This disclosure relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a baseline NIHSS of ≤20. In other embodiments, patients have lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo treatment with a thrombolytic agent and / or decompressive therapy.

The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors. In some embodiments, the SUR1-TRPM4 channel inhibitor is used in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a baseline NIHSS of ≤ 20. In certain embodiments, patients have a lesion volume of less than 300 cm3, less than 140 cm3, or less than 125 cm3 as measured by MRI DWI or CTP. In certain embodiments, patients have a lesion volume expanding at a rate or < 25 mL / h. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo treatment with a thrombolytic agent and / or decompressive therapy.

The present invention provides methods of treating pathological conditions that cause hemolysis, brain edema, acute kidney injury, and anaphylactoid shock, alone or in combination with other agents, using at least one PLA2 inhibitor, the pathological conditions including poisoning, trauma, cerebral malaria, and mast cell diseases. The unexpected versatility, their dosage forms, and combinations of PLA2 inhibitors make them essential medicines for developing countries.

The invention provides a brain tissue edema degree characterization method which comprises the following steps: controlling a cylindrical pressure head to be pressed into an experimental module at a constant rate, and transmitting a signal to a computer by a sensor to obtain a force-displacement curve. And calculating the relaxation amount of the experiment module according to the force-displacement data. The water content in the brain can be qualitatively represented through the obtained mechanical parameters, so that the edema degree of brain tissues is represented. The method not only can realize the characterization of the edema degree of the brain tissue, but also is beneficial to the precision of the measurement technology, accurate data and reliable performance, and can be used for speculating the cause of the edema of the brain.

The application belongs to the technical field of nerve regulation and control engineering, and proposes an Alzheimer's disease electric stimulation system based on cerebrospinal fluid rhythm. First, the first frequency range data and the second frequency range data in the brain wave signal are coupled to obtain cerebrospinal fluid rhythm data. Then, the phase difference between the first frequency range data and the cerebrospinal fluid rhythm data is calculated. Finally, the stimulation frequency is dynamically controlled according to the phase difference, and the stimulation current is dynamically controlled according to the brain tissue water volume fraction. The problem that single frequency stimulation cannot match the specific metabolic needs of non-rapid eye movement sleep and rapid eye movement sleep cycles is solved. The dynamic changes of post-traumatic brain edema, as well as the demand and influence of cerebrospinal fluid rhythm on current control, are considered, the real-time adaptive ability to the dynamic changes of post-traumatic brain edema is improved, and the treatment effect of Alzheimer's disease is guaranteed.

The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo decompressive therapy.

The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a lesion volume of less than 300 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. In certain embodiments, patients have a lesion volume expanding at a rate of <25 mL / h. The patient may have suffered a wake-up stroke. Some embodiments involve treating

The invention discloses a lymphatic system magnetic resonance imaging prediction postoperative brain injury evaluation method and system, and relates to the field of brain injury evaluation, and the method comprises the steps: obtaining multi-modal magnetic resonance imaging image data of a joint anatomy region of a target subject; extracting magnetic resonance imaging function parameters based on the multi-mode magnetic resonance imaging image data; fusing the magnetic resonance imaging function parameters, the brain region white matter fiber integrity parameters, the cerebral hemodynamic indexes and the clinical data of the operation process to construct a multi-dimensional feature vector; and inputting the feature vectors into a hybrid neural network model consisting of a graph convolutional network and a long-short-term memory network, and outputting risk prediction values of postoperative encephaledema, cognitive impairment and white matter injury. According to the method, the limitation that an existing evaluation means is highly dependent on a structural image, functional evaluation is lacked and prediction accuracy is insufficient is broken through, and accurate prediction and intervention of postoperative brain injury based on lymphatic-like function imaging are realized.

The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo decompressive therapy.

The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo decompressive therapy.

The present invention relates to bumetanide derivatives of formula (I) as well as pharmaceutical compositions comprising these compounds for use in the treatment or prevention of neurological diseases / disorders involving Na+—K+-2Cl−—cotransporters (NKCCs), such as stroke, traumatic brain injury (TBI), spinal cord injury (SCI), peripheral nerve injury (PNI), brain edema, or glioma, and particularly for use in the treatment or prevention of stroke. The invention likewise relates to a method of treating or preventing a neurological disease or disorder involving an NKCC, such as stroke, TBI, SCI, PNI, brain edema, or glioma, the method comprising administering a compound of formula (I) to a subject in need thereof.

To provide the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors in combination with mechanical thrombectomy.SOLUTION: In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, the patients have a lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo decompressive therapy.SELECTED DRAWING: None

The invention provides a portable brain tissue edema intelligent monitoring device based on a terahertz spectrum. The portable brain tissue edema intelligent monitoring device comprises a wearing mechanism, a flexible probe and a processing unit, the wearing mechanism is wound on the head of a patient and is used for fixing the flexible probe and the processing unit on the head of the patient to monitor the change of encephaledema; the flexible probe array is installed in the wearing mechanism, and flexible probes are attached to the head of a patient; the processing unit is mounted on one side of the wearing mechanism; the miniature quantum cascade laser is used as an emission source to generate low-frequency terahertz waves so as to enhance the skull penetrating capacity, the high-sensitivity pyroelectric detector is used, the lock-in amplification technology is combined to improve the weak signal detection capacity, the flexible silica gel substrate attaches the monitoring component to the frontal lobe, the temporal lobe, the occipital lobe and other key areas of the head of a patient, and the detection accuracy is improved. Terahertz spectrum signals of different areas of brain tissue are continuously collected, spatial and temporal changes of moisture content and ion concentration are analyzed, an edema thermogram is constructed, and encephaledema is monitored in real time.

The present invention belongs to the technical field of disease drugs, and particularly relates to the application of an engineered attenuated coxsackievirus B3 vector (CVB3(mu)) in the preparation of a drug for treating traumatic brain injury. The present invention discovers that after severe traumatic brain injury in mice, single intraperitoneal injection treatment with CVB3(mu) can reshape the host immune system, can significantly increase the absorption rate of ipsilateral brain edema, and achieve the effect of treating traumatic brain injury; in addition, CVB3(mu) has remarkable safety.

The present invention relates to a method of treating ischemic stroke at risk of cerebral edema or cerebellar edema. Specifically, the invention relates to treatment of ischemic stroke with brain swelling risk by using an SUR1-TRPM4 channel inhibitor in combination with mechanical thrombus removal. In some embodiments, the methods include treating a patient with a large area of hemispherical infarction. In certain embodiments, the patient's lesion volume is less than 140 cm < 3 > or less than 125 cm < 3 > as measured by MRI DWI or CTP. Patients may experience post-waking stroke. Some embodiments relate to treating patients also receiving reduced pressure therapy.

The invention belongs to the technical field of cardio-pulmonary resuscitation, and discloses a system and a method for optimizing a cerebral protection mechanism of hypoxic ischemia encephalopathy after cardio-pulmonary resuscitation, which are characterized in that an intracranial pressure monitoring device is used for monitoring the change of intracranial pressure in real time and evaluating the degree of brain injury and the condition of encephaledema; through intracranial pressure monitoring, a treatment scheme can be adjusted in time, and serious complications of cerebral hernia are prevented; meanwhile, the concentration change of oxyhemoglobin and deoxidized hemoglobin in the brain tissue is monitored through the brain oxygen saturation monitor by utilizing a near infrared spectrum technology, and the oxygenation state of the brain tissue is accurately reflected. Brain oxygen saturation monitoring is beneficial for guiding oxygen therapy and ventilation therapy and optimizing oxygen supply and oxygen consumption balance of brain tissue. The optimization system for the cerebral protection mechanism of the ischemic-hypoxic encephalopathy after the cardio-pulmonary resuscitation operation can remarkably reduce the degree of brain injury, promote neural function recovery and reduce the case fatality rate and disability rate of a patient.

The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors. In some embodiments, the SUR1-TRPM4 channel inhibitor is used in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a baseline NIHSS of ≤ 20. In certain embodiments, patients have a lesion volume of less than 300 cm3, less than 140 cm3, or less than 125 cm3 as measured by MRI DWI or CTP. In certain embodiments, patients have a lesion volume expanding at a rate or < 25 mL / h. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo treatment with a thrombolytic agent and / or decompressive therapy.